FOI release

Freedom of Information responses from the MHRA - week commencing 6 September 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 6 September 2021

From:
Medicines and Healthcare products Regulatory Agency
Published
25 February 2022

Documents

Freedom of Information request on RT-PCR test cycle threshold (FOI 21/904)

HTML

Freedom of Information request on the authorisations of the COVID-19 vaccines (FOI 21/905)

HTML

Freedom of Information request on safety on COVID-19 vaccine (FOI 21/907)

HTML

Freedom of Information request on isolation of the COVID-19 (FOI 21/908)

HTML

Freedom of Information request on composition of COVID-19 vaccines (FOI 21/935)

HTML

Freedom of Information request on contributions to third sector organisations from British Pharmacopoeia (FOI 21/945)

HTML

Freedom of Information request on adverse effects of the cosmetic filler ellanse (FOI 21/952)

HTML

Freedom of Information request on progress of the sacituzumab govitecan approval (FOI 21/954)

HTML

Freedom of Information request on ulcerative colitis clinical study reports (FOI 21/990)

HTML

Freedom of Information request on interactive drug analysis profiles for COVID-19 vaccines (FOI 21/894)

HTML

Freedom of Information request on analysis prints for all coronavirus testing kits (FOI 21-897)

HTML

Freedom of Information request on the grant projects for the periods 2019-2021 (FOI 21/898)

HTML

PDF, 119 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on reports regarding the Corpuls3 defibrillator (FOI 21/911)

HTML

Freedom of Information request on autopsies and death following COVID-19 vaccination (FOI 21/929)

HTML

Freedom of Information request on the benefit and risk balance on the COVID-19 vaccines (FOI 21/959)

HTML

Freedom of Information request on the authorisations of the COVID-19 vaccines (FOI 21/972)

HTML

Freedom of Information request on the composition of the COVID-19 vaccines (FOI 21/1001)

HTML

Freedom of Information request on quantity of mRNA LNP in COVID-19 vaccine (FOI 21/1002)

HTML

Freedom of Information request on documents regarding ado-trastuzumab emtasin (FOI 21/1005)

HTML

Freedom of Information request on the clinical trial data of the Novavax vaccine (FOI 21/1006)

HTML

Freedom of Information request on deaths following COVID-19 vaccination (FOI 21/1009)

HTML

Freedom of Information request on interactive Drug Analysis Profiles for COVID-19 vaccines (FOI 21/1011)

HTML

Freedom of Information request on the access to the RMP (core and annexes) of Herceptin (FOI 21/940)

HTML

PDF, 14.6 MB, 579 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on follow ups for deaths reporting through the yellow card system (FOI 21/941)

HTML

Freedom of Information request on reporting regulations for Adverse Drug Reactions (ADRs) from 2007 to date (FOI 21/983)

HTML

Freedom of Information request on the authorisations of the COVID-19 vaccines (FOI 21/1000)

HTML

Freedom of Information request on the structure of the licensing division (FOI 21/1022)

HTML

Freedom of Information request on monitoring reports of adverse drug reactions in pregnant women following COVID-19 vaccination (FOI 21/863)

HTML

Freedom of Information request on yellow card reports for COVID-19 vaccines (FOI 21/916)

HTML

Freedom of Information request on VAED/VAERD included as an important potential risk in the Risk Management Plan for the COVID-19 vaccines (FOI 21/917)

HTML

Freedom of Information request on the yellow card scheme (FOI 21/922)

HTML

Freedom of Information request on access to the RMP (core and annexes) of Perjeta (pertuzumab) (FOI 21/923)

HTML

PDF, 9.14 MB, 392 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on the yellow card reports from the COVID-19 vaccines (FOI 21/930)

HTML

Freedom of Information request on licensed medicines that contain graphene (FOI 21/936)

HTML

Freedom of Information request on cardiomyopathy reports following the Astrazeneca COVID-19 vaccine (21/953)

HTML

Freedom of Information request on reactions reported in association with COVID-19 vaccines (FOI 21/1023)

HTML

Freedom of Information request on the number of Yellow card reports received (FOI 21/1026)

HTML

Freedom of Information request on weekly summary of Yellow Card reports for COVID-19 vaccines (FOI 21/932)

HTML

PDF, 147 KB, 21 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on COVID-19 vaccination and the Yellow Card reporting scheme (FOI 21/946)

HTML

Freedom of Information request on the ventilators from Manquet (FOI 21/1004)

HTML

Details

The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 6 September 2021

Updates to this page

Published 25 February 2022

Sign up for emails or print this page

Related content